Using results from the STHLM3-MRI study, our aim was to assess the cost-effectiveness of quadrennial PSA-based prostate cancer screening using MRI and a combined biopsy approach in men aged 55 to 69 years in Sweden. This evidence concerns the gene KLK3 and prostate carcinoma.